# Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

> **NCT01532687** · PHASE2 · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 54 (actual)

## Conditions studied

- Adult Alveolar Soft Part Sarcoma
- Adult Angiosarcoma
- Adult Desmoplastic Small Round Cell Tumor
- Adult Epithelioid Hemangioendothelioma
- Adult Epithelioid Sarcoma
- Adult Extraskeletal Myxoid Chondrosarcoma
- Adult Extraskeletal Osteosarcoma
- Adult Fibrosarcoma
- Adult Leiomyosarcoma
- Adult Liposarcoma
- Adult Malignant Peripheral Nerve Sheath Tumor
- Adult Rhabdomyosarcoma
- Adult Synovial Sarcoma
- Adult Undifferentiated Pleomorphic Sarcoma
- Malignant Adult Hemangiopericytoma
- Recurrent Adult Soft Tissue Sarcoma
- Sarcoma
- Stage III Adult Soft Tissue Sarcoma AJCC v7
- Stage IV Adult Soft Tissue Sarcoma AJCC v7

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Gemcitabine Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Pazopanib
- **DRUG:** Pazopanib Hydrochloride
- **OTHER:** Placebo Administration

## Key facts

- **NCT ID:** NCT01532687
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-13
- **Primary completion:** 2019-10-31
- **Final completion:** 2019-10-31
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2021-09-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01532687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01532687, "Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01532687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*